Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers
about
Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association studyChemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait lociIn vitro human cell line models to predict clinical response to anticancer drugsFKBP5 as a selection biomarker for gemcitabine and Akt inhibitors in treatment of pancreatic cancerA genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303Proteomic classification of acute leukemias by alignment-based quantitation of LC-MS/MS data sets.Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine.Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes.Impact of the 1000 genomes project on the next wave of pharmacogenomic discoveryImpact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia.Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines.Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analysesGenome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans.Use of the gamma method for self-contained gene-set analysis of SNP dataGenetic association studies of copy-number variation: should assignment of copy number states precede testing?Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell linesSimultaneous analysis of multiple data types in pharmacogenomic studies using weighted sparse canonical correlation analysisIdentifying the genetic variation of gene expression using gene sets: application of novel gene Set eQTL approach to PharmGKB and KEGG.Population-based in vitro hazard and concentration-response assessment of chemicals: the 1000 genomes high-throughput screening study.The 3' UTR variants in the GRP78 are not associated with overall survival in resectable hepatocellular carcinoma.Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinomaIdentification of genetic variants or genes that are associated with Homoharringtonine (HHT) response through a genome-wide association study in human lymphoblastoid cell lines (LCLs)Current progress in pharmacogenetics.Transcriptomic profiling of taxol-resistant ovarian cancer cells identifies FKBP5 and the androgen receptor as critical markers of chemotherapeutic response.Lymphoblastoid cell lines models of drug response: successes and lessons from this pharmacogenomic model.Mycophenolic acid response biomarkers: a cell line model system-based genome-wide screen.Gemcitabine Cytotoxicity: Interaction of Efflux and Deamination.Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy.Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer.Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translationWatch the GAP: Emerging Roles for IQ Motif-Containing GTPase-Activating Proteins IQGAPs in Hepatocellular CarcinomaAn apparent homozygous deletion in maltase-glucoamylase, a lesson in the evolution of SNP arrays.Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.Genome-wide association study for biomarker identification of Rapamycin and Everolimus using a lymphoblastoid cell line system.FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder.Genetic variations associated with gemcitabine treatment outcome in pancreatic cancer.Integrative gene set analysis: application to platinum pharmacogenomics.Discovery of genetic biomarkers contributing to variation in drug response of cytidine analogues using human lymphoblastoid cell lines.New insights into the synergism of nucleoside analogs with radiotherapy
P2860
Q21261276-D4627227-3377-471D-A5B3-463ECBCC4ECBQ24631841-3261E0D4-505D-47CD-8967-841F346576EDQ27000665-6D23F0CE-CFA3-4FFD-B743-D00953E0659FQ28483623-59B5A014-0806-41D0-ACFA-FC660786CC47Q28943270-0007559A-F23B-4313-A8CA-C0ABA9624FCDQ30558138-8E6E2FFB-057D-4BEF-9FF0-2E28AF6CA541Q30728815-0FCAB16D-FE1D-44A0-907B-4278675F0EF7Q33637143-2252FDDC-456B-4282-90B3-D4C2191E9C5CQ33708200-9A1D2E81-9B5D-40BB-916F-870006E56738Q33799305-9E6D69D9-A8B0-493C-9DDD-58BCCE51B3A8Q33818738-695B5777-FB0E-4349-80C3-3AA743A2AC01Q33825180-1CED094F-0407-4107-BD32-AF8A154B5C51Q33960326-7CEDC8A6-DC0B-43CF-9922-167E65CF1BC6Q34100207-1FF89CBC-3C1F-4CBB-ADBF-0AF7328D87F8Q34228348-2CE72C7D-7AA0-4225-8550-24DED965D032Q34239148-8C3EAA6D-D049-45D3-9DE8-5CFA6625C0D1Q34317474-C2305429-B874-430D-B415-90D793A052CDQ34384986-3339E1AD-B71F-4064-B543-C45B425B4249Q34459766-53589DD7-5492-4D74-A758-7A31659F6D6AQ34708309-9A134766-0A9F-4FAC-8A8F-5B432F879C63Q34925232-51B7280A-E12E-4A2D-B5D0-2721555207ECQ34937030-2312D49F-606C-4D57-8BE4-AC907BE87C2DQ34996898-023E993E-800A-49D9-A1CD-3E05A4B0B026Q35067903-F0F09210-255C-44E0-9F42-36AAAA4A0945Q35068272-3C9ED5DF-61C3-4EAE-A1A5-FC711FD780C6Q35112606-59871C1B-CDA3-4B7B-AD53-84A644FB87C5Q35130652-1E8DA7EC-69A4-4D57-A75E-F0AD64AC0761Q35196480-E840385F-0A43-4493-98F4-875D17F15D58Q35265653-2491045A-BC64-4F34-A585-A878A006F289Q35675274-4A8E9C4E-542A-4E80-A114-5F12480135E9Q35799841-9C7AEEB9-DA97-48EE-850F-6FCDEBD7E25FQ36225463-5AB3CF4F-9A83-42CD-9F36-A1D734EAE017Q36461746-C87ACE90-5E90-4207-84E8-FE6B6EF997B5Q36545157-5BBD7189-00ED-4434-BE72-9C58B06D43FCQ37132395-E5E75FAF-57EE-429C-A60A-E903C8C64695Q37199719-EC68211F-ED97-4FF7-91E7-88C3E9F083F0Q37372466-D9D0469B-B88C-4B2E-A815-AC22762473CCQ37519400-89C3D835-B824-46EC-99B9-D8E5B6B61F5BQ37595491-AAE369CF-D685-48E7-858E-9867ABA2EF59Q38143241-E8BBD6D1-7AFB-4C1E-9EC9-FA18886FF409
P2860
Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Gemcitabine and arabinosylcyto ...... n and drug response biomarkers
@ast
Gemcitabine and arabinosylcyto ...... n and drug response biomarkers
@en
Gemcitabine and arabinosylcyto ...... n and drug response biomarkers
@nl
type
label
Gemcitabine and arabinosylcyto ...... n and drug response biomarkers
@ast
Gemcitabine and arabinosylcyto ...... n and drug response biomarkers
@en
Gemcitabine and arabinosylcyto ...... n and drug response biomarkers
@nl
prefLabel
Gemcitabine and arabinosylcyto ...... n and drug response biomarkers
@ast
Gemcitabine and arabinosylcyto ...... n and drug response biomarkers
@en
Gemcitabine and arabinosylcyto ...... n and drug response biomarkers
@nl
P2093
P2860
P921
P3181
P1433
P1476
Gemcitabine and arabinosylcyto ...... n and drug response biomarkers
@en
P2093
Brooke L Fridley
Gregory Jenkins
Krishna Kalari
Liewei Wang
P2860
P3181
P356
10.1371/JOURNAL.PONE.0007765
P407
P577
2009-11-09T00:00:00Z